In This Section      
 

Search Results

Title:
Phase 1/2 study of navitoclax plus vistusertib in patients with relapsed small cell lung cancer (SCLC) and other solid tumors (ETCTN10070)
Protocol Number:
ETCTN10070
Phase:
Phase I/II
Physician:
Christine Hann
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Purpose:
To evaluate the safety and tolerability of the combination of navitoclax and vistusertib in patients with advanced solid tumors.To determine the maximum tolerated dose (MTD), dose limiting toxicities (DLT), and recommended phase 2 doses (RP2D) of navitoclax and vistusertib.
Eligibility:
Age equal to 18 years.ECOG PS equal to 0 or 1.Life expectancy greater than 12 weeks.Normal organ and marrow function.Must be able to swallow pills.
Treatment:
28 Day Cycle.7 day lead in dose of Navitoclax.Cycle 1, Day 1: Navitoclax once a day and Vistusertib twice a day for the 28 day cycle.Imaging will be completed every 8 weeks.
Population:
Adult
Last Update
03/05/2019 05:03 AM